⚠ COVID-19 INFORMATION: Vaccine Information, Other Resources 

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

Official Title: A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.

NCT04322708
Wechsler, Joshua B., MD, MS
Interventional
No

Contact Information:

Katie Keeley

Research Coordinator

312.227.4656